Bimekizumab Calms Psoriatic Arthritis in Phase 3 'BE' Trials

The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic disease-modifying antirheumatic drug in two trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/975629?src=rss